Novartis Ag (NVS) Other Accumulated Expenses (2009 - 2026)

Novartis Ag has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $15.3 billion for Q2 2026.

• In Q2 2026, Other Accumulated Expenses fell 3.12% year-over-year to $15.3 billion; the TTM figure through Jun 2026 stood at $15.3 billion (down 3.12% YoY), while the FY2025 annual figure was $15.0 billion, up 6.65% from the prior year.
• Other Accumulated Expenses came in at $15.3 billion for Q2 2026 at Novartis Ag, down from $17.4 billion in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $17.4 billion in Q1 2026 to a low of -$5.0 million in Q1 2023.
• Average Other Accumulated Expenses over 5 years is $13.3 billion, with a median of $14.9 billion recorded in 2022.
• Year-over-year, Other Accumulated Expenses tumbled 100.45% in 2023 and surged 300340.0% in 2024.
• Over 5 years, Other Accumulated Expenses stood at $14.8 billion in 2022, then retreated by 11.01% to $13.2 billion in 2023, then advanced by 6.74% to $14.1 billion in 2024, then climbed by 6.65% to $15.0 billion in 2025, then gained by 2.19% to $15.3 billion in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $15.3 billion in Q2 2026, $17.4 billion in Q1 2026, and $15.0 billion in Q4 2025.